galmed pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or fabacs. aramchol is initially being developed for treating non-alcoholic steato-hepatitis, or nash, a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance. galmed pharmaceuticals galmed’s business has been, in its current legal structure, was incorporated in israel on july 31, 2013 as a privately held company. however, operating since 2000 under a different group of companies established in the same year. galmed was co-founded by professor tuvia gilat and allen baharaff, based on professor gilat’s extensive research in fabac’s and nash.
Company profile
Ticker
GLMD
Exchange
Website
CEO
Allen Baharaff
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
GLMD stock data
Latest filings (excl ownership)
20-F
2023 FY
Annual report (foreign)
4 Apr 24
6-K
Current report (foreign)
19 Mar 24
6-K
Current report (foreign)
15 Mar 24
EFFECT
Notice of effectiveness
30 Nov 23
POS AM
Prospectus update (post-effective amendment)
22 Nov 23
6-K
Current report (foreign)
22 Nov 23
6-K
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study
20 Nov 23
POS AM
Prospectus update (post-effective amendment)
1 Nov 23
6-K
Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis
26 Sep 23
6-K
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
22 Sep 23
Latest ownership filings
SC 13G/A
CVI Investments, Inc.
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G/A
Baharaff Allen
12 Feb 24
SC 13G
CVI Investments, Inc.
21 Jul 23
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 23
SC 13G/A
Baharaff Allen
7 Feb 23
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 22
SC 13G/A
Baharaff Allen
11 Feb 22
SC 13G/A
Ibex Investors LLC
27 Jan 22
SC 13G
Nantahala Capital Management, LLC
16 Feb 21
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 11 |
Opened positions | 3 |
Closed positions | 13 |
Increased positions | 0 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 417.02 mm |
Total shares | 5.30 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Baharaff Allen | 3.42 mm | $0.00 |
Biotechnology Value Fund L P | 1.74 mm | $0.00 |
BVF | 89.85 k | $261.47 mm |
Susquehanna International | 25.60 k | $74.49 mm |
Millennium Management | 14.91 k | $43.38 mm |
MS Morgan Stanley | 12.50 k | $37.37 mm |
TSFG | 200.00 | $1.00 k |
Tower Research Capital | 51.00 | $152.00 k |
Bourgeon Capital Management | 34.00 | $102.00 k |
Allworth Financial | 17.00 | $51.00 k |
News
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
10 Apr 24
Why Agenus Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Monday's Mid-Day Session
8 Apr 24
Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
8 Apr 24